We use cookies to improve your experience and for marketing. Read our cookie policy or manage cookies.
Novartis's acquisition of Anthos Therapeutics strengthens its position in the anticoagulant market, promising innovative cardiovascular solutions.
Eli Lilly reports strong Q4 2024 earnings, boosts 2025 guidance; driven by impressive GLP-1 drug sales, it remains an attractive investment opportunity.
Novo Nordisk projects slower sales growth in 2025 due to competition from Eli Lilly, with plans to enhance commercial strategies and expand production.
Novo Nordisk faces investor pressure over CagriSema trials, as mixed results and side effects impact its market standing against competitors like Eli Lilly.
Novo Nordisk experiences a share price surge after amycretin's promising weight-loss trial results, restoring investor confidence despite past setbacks.
Pharmaceutical companies are fiercely competing in the obesity drug market, with Eli Lilly and Novo Nordisk among the major players. Innovations and collaborations are key in this dynamic and lucrative sector.
Novo Holdings finalizes $16.5 billion acquisition of Catalent, enhancing pharmaceutical capabilities amidst regulatory clearance.
60
